News
-
Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .
-
Vectura has announced that it is presenting positive results from a Phase I clinical study of VR942, an inhaled anti-IL-13 monoclonal fragment antibody, at the American Thoracic Society 2017 International Conference. Vectura is partnered with… Read more . . .
-
Chiesi Group has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s MAA for Trimbow beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide MDI. Chiesi has applied to… Read more . . .
-
Submit abstracts by 28 July 2017 at https://aerosol-soc.com/abstract-submission/ Themes for DDL 2017 are Inhaled Therapy in Special Populations, Emerging Therapeutics and Novel Respiratory Medicines, Inhalation Devices and Aerosol Science, and Modelling and Simulations in Inhalation… Read more . . .
-
Acorda Therapeutics will present new data from a Phase 3 trial of its CVT-301 inhaled L-dopa, which it is now calling Inbrija, at the International Congress of Parkinson’s Disease and Movement Disorders (MDS). The company… Read more . . .
-
Lactose manufacturer Meggle has announced the launch of InhaLac 500 micronized lactose for dry powder inhalation formulations, saying “Combined with high quality and safety, this material meets the most demanding individual dry powder inhalation formulation… Read more . . .
-
Aptar Pharma has announced that its partner Takeda Pharmaceuticals has received approval from the EMA to market a multidose version of its Instanyl fentanyl nasal spray that includes Aptar’s e-Lockout integrated electronic lockout device. According… Read more . . .
-
Arikayce inhaled amikacin deveoper Insmed Incorporated has announced the appointments of Paolo Tombesi as Chief Financial Officer, Paul Streck as Chief Medical Officer, and Eugene Sullivan as Chief Product Strategy Officer. Tombesi was most recently… Read more . . .
-
Milestone Pharmaceuticals has announced positive results from the Phase 2 NODE-1 study of intranasal etripamil for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a type of cardiac arrhythmia. The double-blind dose ranging study… Read more . . .
-
Inhalation Asia 2017, which will take place September 13-15, has announced a change of venue from Hong Kong to Macau. The meeting will now take place on the campus of the University of Macau. Dr.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland